LOKREN PILLS 20MG
LOKREN PILLS 20MG - 28 tabs
Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
Mechanism of action
Lokren has a hypotensive, antianginal effect.
Indications and usage
prevention of stress angina attacks.
Hypersensitivity to betaxolol;
severe chronic heart failure IIB-III;
AV block II and III degree (without connecting an artificial pacemaker);
Prinzmetal angina pectoris;
syndrome of weakness of the sinus node (including sinoatrial blockade);
combination therapy with sultopride and flactafenin;
simultaneous administration of MAO inhibitors;
cardiomegaly (without signs of heart failure);
age up to 18 years (efficacy and safety have not been established).
Due to the presence of lactose, Lokren is contraindicated in:
with congenital galactosemia;
glucose / galactose malabsorption syndrome or lactase deficiency.
Pregnancy and Breastfeeding
Application of Locri in pregnancy is possible only when the benefit to the mother outweighs the potential risk to the fetus and / or the child.
Beta-blockers penetrate into breast milk. The risk of hypoglycemia or bradycardia has not been studied, so breastfeeding should be stopped during treatment.
Nervous system disorders: fatigue, weakness, dizziness, headache, drowsiness or insomnia, nightmares, depression, anxiety, confusion or short-term memory loss, hallucinations, asthenic syndrome, muscle weakness, paresthesias in the extremities (in patients with "intermittent" limp, Raynaud's syndrome), tremor.
Cardiovascular system: sinus bradycardia, palpitations, orthostatic hypotension, myocardial conduction disturbance, AV block (up to cardiac arrest), arrhythmias, weakening of myocardial contractility, development (or aggravation) of heart failure symptoms (swelling of ankles, feet, legs), pronounced decrease in blood pressure, manifestation of angiospasm (decrease in peripheral circulation, cooling of the lower extremities, Raynaud's syndrome), chest pain.
On the part of the digestive system: dryness of the mucous membranes of the oral cavity, nausea, vomiting, abdominal pain, constipation or diarrhea, abnormal liver function (dark urine, sclera or skin yellowness, cholestasis), change in taste.
On the part of the respiratory system: nasal congestion, difficulty breathing in the appointment of large doses (loss of selectivity) and / or in predisposed patients - laryngitis and bronchospasm.
On the part of the senses: visual disturbances, reduced secretion of the lacrimal glands, dryness and soreness of the eyes, conjunctivitis.
On the part of the skin: increased sweating, skin hyperemia, rash, psoriasis-like skin reactions, exacerbation of the course of psoriasis.
Allergic reactions: skin rash, itching, urticaria.
On the part of the endocrine system: hyperglycemia in patients with non-insulin-dependent diabetes mellitus, hypoglycemia in patients receiving insulin, a hypothyroid state.
Effect on the fetus: intrauterine growth retardation, hypoglycemia, bradycardia.
Others: back pain, arthralgia, decreased libido, reduced potency, "withdrawal" syndrome (increased angina attacks, increased blood pressure).
Laboratory data: in rare cases, antinuclear antibodies appear, which only in exceptional cases is accompanied by clinical manifestations of the type of systemic lupus erythematosus, which pass when treatment is stopped.
Dosage and administration
Lokren accept inside, without chewing, washing down with enough liquid. Initial dose - 1 table. (20 mg) per day.
Dosage in patients with renal failure:
The dose of Locrox should be set in accordance with the patient's kidney function: a dose change is not required with Cl creatinine> 20 ml / min. However, at the beginning of treatment, it is recommended to conduct clinical observation until equilibrium levels of the drug in the blood are reached (4 days on average).
In patients with severe renal insufficiency (Cl creatinine <20 ml / min), the recommended initial dose is 5 mg / day (in patients on hemodialysis, regardless of the frequency and time of hemodialysis sessions).
Dosage in patients with liver failure:
In patients with hepatic insufficiency, a change in the dose of Locri is usually not required.However, at the beginning of therapy, more careful clinical observation of the patient is recommended.
In a dry, dark place at a temperature of no higher than 20 ° C.